We found that MLL-AF9-driven AML cells generated from bone marrow progenitor cells of Trp53(−/−) mice were more sensitive to decitabine treatment than their p53-intact counterparts in vivo. The gene discussed is KMT2A; the disease is acute myeloid leukemia.